In many medical device companies, Post-Market Clinical Follow-up (PMCF) is still seen as a burden — a bureaucratic requirement introduced by the EU MDR (EU 2017/745) that adds cost and pressure to already overloaded regulatory teams.
That view is increasingly short-sighted.
Companies that treat PMCF purely as compliance are missing a significant strategic opportunity.
The MDR changed the lifecycle of clinical evidence
One of the most important shifts introduced by the MDR is that clinical evidence no longer ends at market approval.
Under the previous framework, manufacturers could often rely on equivalence claims and passive surveillance. Today, the MDR requires proactive and continuous post-market clinical data generation throughout the life of the device.
PMCF, defined in Article 83 and Annex XIV Part B, is not a single activity but a continuous evidence system. Its outputs feed multiple regulatory documents, including the Clinical Evaluation Report (CER), the Risk Management File, and the Periodic Safety Update Report (PSUR).
Guidance documents such as MDCG 2020-7 (PMCF Plan Template) and MDCG 2020-6 (Clinical Evaluation) clarify that PMCF is an integral part of the clinical evidence framework.
The real question for manufacturers is no longer whether to conduct PMCF.
It is how to design it so that it generates meaningful and defensible clinical evidence.
Why many PMCF plans fail
In practice, many PMCF plans share the same structural weaknesses.
Objectives are often generic, repeating regulatory language rather than addressing the specific device. Statements such as “confirm long-term safety” appear frequently without defining measurable clinical outcomes, time horizons, or acceptance thresholds.
Methods are also frequently insufficient. Literature reviews and user surveys are sometimes proposed even for higher-risk devices, where these approaches alone rarely satisfy MDR expectations.
The consequences are predictable: requests for clarification from Notified Bodies, delays in certification, or PMCF programs that generate data too weak to support future CER updates.
The industry is increasingly seeing that pre-market data alone is no longer enough. Clinical evidence must evolve continuously after commercialization.
Building a scientifically sound PMCF strategy
An effective PMCF plan starts with a structured gap analysis.
Manufacturers must identify what is already known from pre-market studies, what uncertainties remain, and which questions must be addressed through post-market data.
Common gaps include:
- long-term safety outcomes
- device performance in real-world clinical settings
- rare adverse events not detectable in pre-market trials
From this analysis, the PMCF plan should define specific and measurable objectives tied to clinically relevant outcomes for the device’s intended population and indication.
Method selection then depends on the risk class of the device and the level of evidence required.
For Class III devices, dedicated PMCF studies with raw data collection are often necessary. For some Class IIb devices, structured real-world data sources, such as disease registries, may provide sufficient evidence if the study design is rigorous.
Feasibility matters as much as methodology
Scientific rigor must be balanced with operational feasibility.
Overly ambitious PMCF commitments, such as enrolling hundreds of patients in a short timeframe for a rare indication, often prove unrealistic. When plans cannot be executed, manufacturers face missing data, regulatory scrutiny, and potential compliance risks.
A robust PMCF strategy therefore requires both methodological strength and operational realism.
Expanding the role of real-world data
The MDR allows manufacturers to use a broader range of post-market evidence sources, including:
- prospective or retrospective cohort studies
- disease registries
- analyses of Electronic Health Record data
- structured user surveys and systematic literature reviews
For certain therapeutic areas, particularly oncology or cardiovascular medicine, established registries can provide valuable real-world evidence if data collection is properly integrated into the PMCF strategy.
New challenges for digital and AI-enabled devices
For software and AI-enabled medical devices, PMCF introduces additional complexity.
Performance can evolve over time due to software updates, changes in user behavior, or shifts in input data distributions. PMCF strategies for these devices must therefore include continuous performance monitoring, not only episodic safety assessments.
PMCF as a strategic asset
When designed properly, PMCF does far more than maintain regulatory compliance.
Post-market clinical data demonstrates that a device performs effectively in real-world clinical practice, strengthening discussions with hospitals, procurement committees, and health technology assessment bodies. It can support reimbursement negotiations, enable new clinical indications, and identify emerging safety signals early.
In this sense, a well-designed PMCF program becomes a real-world evidence platform, not just a regulatory exercise.
From compliance to competitive advantage
PMCF under MDR is too complex, and too strategically relevant, to be treated as a routine regulatory task.
Companies that approach it with methodological rigor are building a long-term evidence asset.
Those that treat it as a bureaucratic obligation risk accumulating an evidence gap that will eventually slow regulatory progress and market expansion.
The difference lies in perspective:
PMCF is no longer just about compliance. It is about building the clinical evidence that sustains the device throughout its entire lifecycle.